VIR Vir Biotechnology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1706431 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,696.0%
TTM net income YoY63.0%
TTM EPS YoY67.4%
Revenue 3-yr CAGR36.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-69.8%
Net margin-61.0%
FCF margin-46.8%
EBITDA margin-66.1%
Returns
ROE-21.8%
ROA-17.3%
ROIC (approx.)-25.6%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets19.4%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | -$188,000 | $238.95M | -$29,000 | $64.07M | $240,000 | $1.21M | $3.03M | $12.37M |
| Cost of revenue | — | $0 | — | — | — | $11,000 | $0 | $684,000 |
| Gross profit | — | $238.95M | — | — | — | $1.20M | $3.03M | $11.69M |
| R&D expense | $80.04M | $135.28M | $108.92M | $88.35M | $151.46M | $97.51M | $118.64M | $106.08M |
| SG&A expense | $24.43M | $30.20M | $23.34M | $23.62M | $22.23M | $22.28M | $23.94M | $26.70M |
| Operating income | -$104.66M | $73.47M | -$132.29M | -$47.92M | -$173.44M | -$118.42M | -$139.55M | -$117.15M |
| Pretax income | -$96.39M | $80.26M | -$125.53M | -$43.06M | -$162.97M | -$110.79M | -$120.95M | -$104.67M |
| Income tax | -$143,000 | $179,000 | $170,000 | -$137,000 | $168,000 | $170,000 | $16,000 | -$86,000 |
| Net income | -$96.25M | $80.08M | -$125.69M | -$42.92M | -$163.14M | -$110.96M | -$120.97M | -$104.59M |
| EBITDA | -$101.96M | $76.17M | -$129.48M | -$45.02M | -$170.54M | -$115.52M | -$136.68M | -$114.26M |
| EPS (basic) | -0.57 | 0.48 | -0.85 | — | -1.17 | -0.80 | -0.88 | — |
| EPS (diluted) | -0.57 | 0.47 | -0.85 | — | -1.17 | -0.80 | -0.88 | — |
| Weighted avg. shares (diluted) | 169.28M | 168.88M | 147.36M | — | 138.93M | 138.45M | 137.47M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $218.87M | $278.73M | $274.16M | $232.19M | $170.08M | $211.10M | $273.57M | $318.69M |
| Short-term investments | $235.77M | $249.86M | $196.28M | $228.75M | $327.75M | $387.64M | $517.37M | $678.05M |
| Current assets | $508.27M | $573.74M | $522.99M | $514.08M | $545.68M | $735.71M | $932.21M | $1.04B |
| PP&E, net | $47.77M | $50.43M | $53.16M | $55.62M | $58.20M | $60.80M | $61.68M | $63.18M |
| Goodwill | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M | $16.94M |
| Intangibles | $7.63M | $7.70M | $7.78M | $7.85M | $7.92M | $8.00M | $8.07M | $8.12M |
| Total assets | $1.11B | $1.21B | $1.03B | $1.00B | $1.02B | $1.19B | $1.31B | $1.40B |
| Current liabilities | $80.66M | $94.96M | $73.56M | $92.81M | $75.22M | $105.00M | $137.29M | $119.66M |
| Total liabilities | $215.82M | $232.31M | $212.82M | $237.55M | $223.35M | $245.06M | $263.91M | $248.43M |
| Shareholders' equity | $896.04M | $982.49M | $812.76M | $765.28M | $796.10M | $947.47M | $1.04B | $1.15B |
| Shares outstanding | 169.41M | 169.19M | 161.23M | 139.47M | 139.02M | 138.89M | 138.06M | 136.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$106.08M | $123.33M | -$132.39M | -$25.88M | -$167.57M | -$120.22M | -$78.12M | -$87.64M |
| Capital expenditure | $34,000 | $32,000 | $390,000 | $348,000 | $317,000 | $2.54M | $1.63M | $2.41M |
| Free cash flow | -$106.11M | $123.29M | -$132.78M | -$26.22M | -$167.89M | -$122.76M | -$79.75M | -$90.04M |
| Investing cash flow | $44.56M | -$197.14M | $11.84M | $86.65M | $40.45M | $56.46M | $126.82M | $140.74M |
| Financing cash flow | $1.63M | $78.38M | $162.52M | $1.04M | $102,000 | $2.05M | $598,000 | $1.26M |
| Depreciation & amortization | $2.70M | $2.70M | $2.81M | $2.90M | $2.90M | $2.90M | $2.87M | $2.89M |
| Stock-based compensation | $10.46M | $12.39M | $12.09M | $11.21M | $11.36M | $12.45M | $14.06M | $15.84M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.